Revvity (NYSE: RVTY) reported second-quarter fiscal year 2026 results with pro forma organic growth of 3% and adjusted earnings per share of $1.41, exceeding the high end of prior guidance. The performance was driven by strong diagnostics demand and unexpected tariff refunds, prompting an upward revision to full-year outlooks.

Segment Performance

The company’s results reflect a divergence between its two primary segments. The Diagnostics segment delivered robust expansion, while Life Sciences faced headwinds from software contract timing. All figures are on a pro forma basis, excluding the immunodiagnostics business in China, which is pending divestiture.

Diagnostics revenue rose 11% organically to $352 million, supported by mid-teens growth in reproductive health and high single-digit growth in immunodiagnostics outside China. Conversely, Life Sciences revenue declined 3% organically to $359 million, primarily due to a 20% decline in the Signals software business against difficult year-ago comparisons. Excluding software, sales into pharma and biotech customers grew in the low single digits.

Guidance Revision

Management raised full-year guidance, citing improved market conditions and strategic reinvestments. The updated outlook reflects a more optimistic view of the second half, particularly for the Signals software business and instrument backlog conversion.

• Organic Growth: Raised to 4-5% from prior 3-4%.
• Adjusted EPS: Raised to $5.30-$5.40 from prior guidance.
• Adjusted Operating Margin: Expected at approximately 28.7%, up 30 bps from prior guidance.
• Total Revenue: Projected between $2.83 billion and $2.86 billion.

The company noted that approximately half of the Q2 EPS upside was attributable to tariff refunds, while the remainder came from stronger underlying margins and tax timing benefits. These refunds are considered non-recurring, though management plans to reinvest about half of the benefit into strategic initiatives and supply chain improvements.

What the Numbers Show

A significant divergence exists between reported revenue trends and order backlog health. While Life Sciences revenue declined 3% organically, management highlighted that instrument backlog exited the quarter at its highest level in three to four years. This suggests a timing lag where orders are converting to revenue later than usual, particularly for complex instruments like the Opera Phenix OptiQ. Additionally, the Signals software segment’s 20% organic decline contrasts sharply with its double-digit annualized portfolio value (APV) growth, indicating that current revenue dips are driven by contract renewal timing rather than fundamental customer attrition or loss of market share.

Revvity (NYSE: RVTY) has generated an average annual return of 14.61% over the past 15 years, outperforming the broader market by 1.11% on an annualized basis.

The company currently holds a market capitalization of $16.24 billion. Historical performance data indicates that an initial investment of $1,000 in RVTY stock 15 years ago would have grown to $7,469.50 today, based on a share price of $145.52 at the time of writing.

What the Numbers Show

The growth trajectory highlights the impact of compounded returns on long-term capital appreciation. The difference between the initial $1,000 investment and the current value of $7,469.50 illustrates how consistent annualized outperformance accumulates over a multi-year horizon.